Bernstein Maintains Outperform on Alnylam Pharmaceuticals, Lowers Price Target to $310

Benzinga · 01/07 17:19
Bernstein analyst William Pickering maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and lowers the price target from $314 to $310.